Aftin-4 is an inducer of amyloid-β (1-42) (Aβ42). It selectively increases extracellular Aβ42 over Aβ40 production in N2a-AβPP695 cells when used at concentrations ranging from 1 to 100 mM. In vivo, aftin-4 (3-20 nmol/animal, i.c.v.) increases hippocampal Aβ42 content, lipid peroxidation, and production of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in mice. It also induces spatial working and spatial reference memory deficits in mice, effects that are reversed by co-administration of the γ-secretase inhibitor BMS-299,897.
Aftin 4, is an Amyloid-β42 (Aβ42) inducer, that increases Aβ1-42 levels in vivo in mice and provokes rapidly a sustained toxicity highly reminiscent of Alzheimer’s disease (AD).
Aftin-4, an amyloid forty-two inducer, activates γ-secretase, promoting the generation of amyloid-β-1-42 (Aβ1-42) from amyloid-β protein precursor. Aftin-4 increased Aβ-1-42, but not Aβ-1-40 in mouse hipppocampus, accompanied by learning deficits and mitochondrial ultrastructural changes similar to those found in the brains of patients with AD. Aftin-4 can thus be used to induce a rapid, acute Alzheimer′s disease-like toxicity in the rodent brain.
Aftin-4 increases Aβ1-42 levels in vivo in mice and provokes rapidly a sustained toxicity highly reminiscent of Alzheimer’s disease (AD). Aftin-4 is administered at increasing doses, between 3 and 20 nmol/mouse, into the lateral ventricle and animals are sacrificed at various time points, between 3 to 14 days after injection. The hippocampus is dissected out the contents in Aβ1-40 or Aβ1-42 is determined using a mouse ELISA assay. Aftin-4 dose-dependently and significantly increases Aβ1-42 content, up to +216% at the highest dose tested[1].
[1] ARNAUD HOCHARD. Aftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer’s disease[J]. Journal of Alzheimer’s Disease, 2013, 35 1: 107-120. DOI:
10.3233/jad-121777[2] JOHANN MEUNIER. Brain toxicity and inflammation induced in vivo in mice by the amyloid-β forty-two inducer aftin-4, a roscovitine derivative.[J]. Journal of Alzheimer’s Disease, 2015, 44 2: 507-524. DOI:
10.3233/jad-140711